Integra LifeSciences Holdings Corporation (IART)

Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer

PRINCETON, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART...

Integra LifeSciences Announces Key Executive Appointments

PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (Nasdaq: IART...

Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself

Issued on behalf of Conexeu Sciences Inc. A sector analysis of regenerative medicine — the science of...

The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It

Issued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of...

Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference

PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART...

A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — In healthcare, the market tends...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts Canada...

Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference

PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART...

Form SD - Specialized disclosure report

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It Canada NewsWire NEW...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors